Tirzepatide, a drug that activates two gut hormones, helps people lose weight and improves metabolism. Early studies show it can also lower the number of breathing pauses (AHI) in sleep apnea, likely by shrinking fat around the airway and cutting inflammation. This means it might be a useful tool for biohackers looking to boost sleep quality and overall health, but it still needs a doctor’s prescription and monitoring.

Obstructive sleep apnea (OSA) is a breathing disorder characterized by repeated, com-plete, and partial upper airway blockage, which results in disturbances in sleep patterns, neurocog-nitive functions, and hypoxemia. It is strongly linked to obesity and metabolic dysfunction, con-tributing to cardiovascular and neurocognitive complications. Tirzepatide, a dual GIP/GLP-1 re-ceptor agonist, has shown significant potential for weight loss with metabolic benefits, making it a potential therapeutic strategy for OSA by reducing fat deposition around the upper airway, im-proving insulin sensitivity, and lowering systemic inflammation. Emerging clinical studies have shown potential improvement in apnea-hypopnea index (AHI) and oxygenation. In this review, we have explored the role of tirzepatide in managing OSA by targeting obesity, metabolic dysfunction, and airway stability. Here, we have also examined tirzepatide mechanisms by highlighting clinical trials to find its efficacy in reducing OSA severity and improving patient outcomes.